Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > BUSINESS
BUSINESS
- Takeda to Terminate License Agreement with AMAG for Iron Deficiency Anemia Treatment Ferumoxytol
January 6, 2015
- Sumitomo Dainippon to Reorganize Production Bases to Create Efficient, Low-Cost Production System
January 6, 2015
- AnGes MG Changes Development Strategy for NF-κB Decoy Oligo
January 5, 2015
- Shin Nippon Biomedical Laboratories to Tie Up with US CRO for Clinical Development Services
January 5, 2015
- Opdivo Receives Accelerated Approval in US for Malignant Melanoma: BMS
January 5, 2015
- Bayer Yakuhin Files PAH Drug Iloprost for Approval
December 26, 2014
- Sumitomo Dainippon Aims to File Lurasidone in Japan in FY2015 following Favorable Asian PIII Study Results
December 26, 2014
- Chugai Wins First Round in Patent Infringement Lawsuit for Oxarol Ointment
December 26, 2014
- Otsuka Obtains Rights from ARIAD to Develop, Commercialize Ponatinib in Japan and Other Asian Countries
December 26, 2014
- Taiho Completes NDA Submission for Lonsurf in US
December 26, 2014
- Takeda Files NDA for Glatiramer Licensed from Teva for Relapse Prevention of Multiple Sclerosis
December 26, 2014
- Astellas Expands Scope of Collaboration with Cytokinetics in Skeletal Muscular Disease Field
December 25, 2014
- NDA for Selexipag Filed in US by Actelion: Nippon Shinyaku
December 25, 2014
- Fujifilm Completes Acquisition of Kalon Biotherapeutics
December 24, 2014
- AZ, Quintiles Create New Drug Development Team, Fusing Pharma’s Expertise with CRO’s Knowhow
December 24, 2014
- Ono Licenses Exclusive Worldwide Rights for BTK Inhibitor to Gilead Excluding East and South East Asia
December 22, 2014
- Chugai, Yakult File Xeloda, Elplat for Postoperative Adjuvant Chemotherapy for Gastric Cancer
December 22, 2014
- Poteligeo Now Indicated for Chemotherapy-Naïve CCR4-Positive ATL: Kyowa Kirin
December 19, 2014
- Taiho’s Abraxane Gets Nod for Unresectable Pancreatic Cancer
December 19, 2014
- Takeda Names Sanofi’s Plump as New R&D Head
December 19, 2014
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…